The risk of mortality in patients with COVID-19 with pre-diagnosis use of NSAIDs: a meta-analysis.

Published on Apr 21, 2021in Inflammopharmacology4.473
路 DOI :10.1007/S10787-021-00810-1
Chia Siang Kow12
Estimated H-index: 12
(Monash University Malaysia Campus),
Syed Shahzad Hasan20
Estimated H-index: 20
(University of Newcastle)
Sources
Abstract
The notion that the use of non-steroidal anti-inflammatory drugs (NSAIDs) may lead to adverse outcomes upon acquisition of coronavirus disease 2019 (COVID-19) should be discredited with a review of the real-life evidence. We aimed to perform a meta-analysis to summarize the risk of mortality with the preadmission/pre-diagnosis use of NSAIDs in patients with COVID-19. A systematic literature search was performed to identify eligible studies in electronic databases. The outcome of interest was the development of a fatal course of COVID-19. Adjusted hazard ratio or odds ratio/relative risk and the corresponding 95% confidence interval from each study were pooled using a random-effects model to produce pooled hazard ratio and pooled odds ratio, along with 95% confidence interval. The meta-analysis of 3 studies with a total of 2414 patients with COVID-19 revealed no difference in the hazard for the development of a fatal course of COVID-19 between NSAID users and non-NSAID users (pooled hazard ratio = 0.86; 95% confidence interval 0.49-1.51). Therefore, NSAIDs should not be avoided in patients who are appropriately indicated during the COVID-19 pandemic.
馃摉 Papers frequently viewed together
References12
Newest
The most severe clinical manifestations of the Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are due to an unbalanced immune response and a pro-thrombotic hemostatic disturbance, with arterial hypertension or diabetes as acknowledged risk factors. While waiting for a specific treatment, the clinical management of hospitalized patients is still a matter of debate, and the effectiveness of treatments to manage clinical manifestations a...
Source
#1Jungchan Park (SMC: Samsung Medical Center)H-Index: 5
#2Seung-Hwa Lee (SMC: Samsung Medical Center)H-Index: 6
Last. Kwangmo Yang (SMC: Samsung Medical Center)H-Index: 5
view all 5 authors...
Non-steroidal anti-inflammatory drugs (NSAIDs) have been widely used in patients with respiratory infection, but their safety in coronavirus disease 19 (Covid-19) patients has not been fully investigated. We evaluated an association between NSAID use and outcomes of Covid-19. This study was a retrospective observational cohort study based on insurance benefit claims sent to the Health Insurance Review and Assessment Service of Korea by May 15, 2020. These claims comprised all Covid-19-tested cas...
Source
#1Laila Carolina Abu Esba (National Guard Health Affairs)H-Index: 3
#2Rahaf Ali Alqahtani (National Guard Health Affairs)H-Index: 2
Last. Gahdah Mardawi (National Guard Health Affairs)H-Index: 1
view all 6 authors...
Introduction Ibuprofen disappeared from the pharmacy shelves during the 2019 coronavirus (COVID-19) pandemic. However, a while later, information circulated that ibuprofen should be avoided as it could worsen COVID-19 symptoms. The aim of our study was to assess the association of acute and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) with worse COVID-19 outcomes. Methods We did a prospective cohort study between April 12 and June 1, 2020. Adults consecutively diagnosed with COVI...
Source
#1Jennifer S. Chen (Yale University)H-Index: 13
#2Mia Madel Alfajaro (Yale University)H-Index: 13
Last. Craig B. Wilen (Yale University)H-Index: 35
view all 7 authors...
Identifying drugs that regulate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its symptoms has been a pressing area of investigation during the coronavirus disease 2019 (COVID-19) pandemic. Nonsteroidal anti-inflammatory drugs (NSAIDs), which are frequently used for the relief of pain and inflammation, could modulate both SARS-CoV-2 infection and the host response to the virus. NSAIDs inhibit the enzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), which me...
Source
#1Aditya SahaiH-Index: 3
#2Rohan BhandariH-Index: 5
Last. Anu AggarwalH-Index: 5
view all 18 authors...
Coronavirus disease-2019 (COVID-19) caused by SARS-CoV-2 is an ongoing viral pandemic marked by increased risk of thrombotic events. However, the role of platelets in the elevated observed thrombotic risk in COVID-19 and utility of anti-platelet agents in attenuating thrombosis is unknown. We aimed to determine if human platelets express the known SARS-CoV-2 receptor-protease axis on their cell surface and assess whether the anti-platelet effect of aspirin may mitigate risk of myocardial infarct...
Source
#1Kristian Kragholm (AAU: Aalborg University)H-Index: 25
#2Thomas A. Gerds (UCPH: University of Copenhagen)H-Index: 61
Last. Christian Torp-PedersenH-Index: 131
view all 13 authors...
Recommendations regarding ibuprofen use in relation to coronavirus disease 2019 (COVID-19) have been conflicting. We examined the risk of severe COVID-19 between ibuprofen-prescribed and non-ibuprofen patients with COVID-19 in a nationwide register-based study of patients with COVID-19 in Denmark between the end of February 2020 and May 16, 2020. Patients with heart failure (n聽=聽208), 14聽days before COVID-19 vs. 鈮ぢ14聽days of COVID-19 were 17.1% (95% CI 12.3-22.0) vs. 14.3% (95% CI 7.1-23.1). In ...
Source
#1Zaid Imam (Beaumont Health)H-Index: 8
#2Fadi Odish (Beaumont Health)H-Index: 3
Last. Alexandra Halalau (Oakland University)H-Index: 8
view all 10 authors...
INTRODUCTION: Higher comorbidity and older age have been reported as correlates of poor outcomes in COVID-19 patients worldwide, however US data is scarce. We evaluated mortality predictors of COVID-19 in a large cohort of hospitalized patients in the US. DESIGN: Retrospective, multicenter cohort of inpatients diagnosed with COVID-19 by RT-PCR from March 1-April 1,2020 was performed, and outcome data evaluated from March 1-April 17, 2020. Measures included demographics, comorbidities, clinical p...
Source
During the COVID-19 pandemic, a correspondence, published at the Lancet Respiratory Medicine, that linked angiotensin-converting enzyme inhibitors, angiotensin receptor blockers聽and聽ibuprofen to a higher risk of SARS CoV-2 infection and complications, has influenced, when adopted by official health authorities, the practical management of COVID-19 with regard聽to non-steroidal anti-inflammatory drugs that were avoided in all COVID-19 management protocols all over the world. This manuscript discus...
Source
#1Lars Christian LundH-Index: 10
Last. Anton Potteg氓rd (University of Southern Denmark)H-Index: 37
view all 11 authors...
BACKGROUND Concerns over the safety of non-steroidal anti-inflammatory drug (NSAID) use during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been raised. We studied whether use of NSAIDs was associated with adverse outcomes and mortality during SARS-CoV-2 infection. METHODS AND FINDINGS We conducted a population-based cohort study using Danish administrative and health registries. We included individuals who tested positive for SARS-CoV-2 during the period 27 Februa...
Source
#1Lucinda SmartH-Index: 1
#2Neil FawkesH-Index: 1
Last. Neil ShahH-Index: 1
view all 7 authors...
The coronavirus disease 19 (COVID-19) pandemic is currently the most acute healthcare challenge in the world. Despite growing knowledge of the nature of Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2), treatment options are still poorly defined. The safety of non-steroidal anti-inflammatory drugs (NSAIDs), specifically ibuprofen, has been openly questioned without any supporting evidence or clarity over dose, duration, or temporality of administration. This has been further conflict...
Source
Cited By2
Newest
#1Vassilios Liakopoulos (A.U.Th.: Aristotle University of Thessaloniki)H-Index: 32
#2Stefanos Roumeliotis (A.U.Th.: Aristotle University of Thessaloniki)H-Index: 14
Last. Nikolaos Papanas (DUTH: Democritus University of Thrace)H-Index: 45
view all 4 authors...
Although coronavirus disease (COVID-19) is primarily a respiratory disease, the kidney may be among the target organs of infection with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). Independently of baseline kidney function, acute kidney injury (AKI) is a common complication of COVID-19, associated with increased mortality and morbidity. Most frequently, COVID-19 causes acute tubular necrosis; however, in some cases, collapsing focal segmental glomerulosclerosis and direct viral ...
Source
#1E. L. Nasonov (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 1
#2A. M. LilaH-Index: 1
Last. S. V. Moiseev (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 1
view all 11 authors...
In mid-2021, the SARS-CoV-2 (Severe Acute Respiratory coronavirus 2) infection, which caused the coronavirus disease (COVID-19) pandemic, affected more than 157 million people in all regions of the world and led to more than 3.2 million deaths. It is assumed that elderly age, uncontrolled inflammation, anti-inflammatory therapy, comorbid pathology, genetic and other factors can potentially lead to an increase in 鈥渟ensitivity鈥 to viral and bacterial infections, including SARS-CoV-2. The new versi...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.